Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...
Pharmabiz1h
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC
New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...
Natera Reports Third Quarter 2024 Financial Results
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for ...
MedPage Today23h
Year in Review: Early Breast Cancer
News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...
Mena FN23h
Curevac Announces Financial Results For The Third Quarter And First Nine Months Of 2024 And Provides Business Update
in patients with resected glioblastoma in September 2024 at the European Society for Medical Oncology (ESMO) Congress and in November at the Society for Immunotherapy of Cancer (SITC) and the Society ...